PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
11 December 2007 Board of Directors
University of Virginia Patent
Foundation Licenses Silver Nanoparticle Technology to U.Va. Start-Up PluroGen Therapeutics Inc.
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE
BIO LIFE TECH CONFERENCE 2007
IN BALTIMORE, MARYLAND
(Charlottesville, VA, December 11, 2007) – PluroGen Therapeutics, Inc. today announced it presented at the Bio
Life Tech Conference in Baltimore , Maryland.
Making the presentation for PluroGen, Neal G. Koller, President & CEO of PluroGen commented “For PluroGen to
be selected to present at this prestigious conference is acknowledgement of our progress. The exposure the
company received and the contacts we made are invaluable.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen is a wound healing company commercializing its patent-protected
gel technology platform that provides superior and differentiated physical and bio-active benefits to wound
healing. The platform delivers drug and non-drug compounds as protected and advanced therapeutic products
for simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for the
6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
The company’s first two products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG, are topical antimicrobial
products. Currently in routine use, PluroGel™ TAG is showing superior results at the University of Virginia Medical
Center on more than 2,000 patients, both chronic wound and burn. PluroGen’s management team, operational
partners, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s
target markets of wound care and burn care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
About Bio Life Tech Conference 2007
Bio Life Tech 2007 is the venture capital showcase for promising young companies. It serve as a gathering place
for entrepreneurs and those organizations funding and servicing them in order to enable them to grow and
succeed. Bio Life Tech is as a part of Early Stage East, founded in 1998 as a non-profit organization, and grown
from a single-day venture capital fair to a year-round series of programs & events. Events showcase
entrepreneurs from up and down the East Coast in order for them to effectively obtain venture capital and
successfully start break-away businesses.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
President & CEO
11 December 2007 Board of Directors
University of Virginia Patent
Foundation Licenses Silver Nanoparticle Technology to U.Va. Start-Up PluroGen Therapeutics Inc.
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE
BIO LIFE TECH CONFERENCE 2007
IN BALTIMORE, MARYLAND
(Charlottesville, VA, December 11, 2007) – PluroGen Therapeutics, Inc. today announced it presented at the Bio
Life Tech Conference in Baltimore , Maryland.
Making the presentation for PluroGen, Neal G. Koller, President & CEO of PluroGen commented “For PluroGen to
be selected to present at this prestigious conference is acknowledgement of our progress. The exposure the
company received and the contacts we made are invaluable.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen is a wound healing company commercializing its patent-protected
gel technology platform that provides superior and differentiated physical and bio-active benefits to wound
healing. The platform delivers drug and non-drug compounds as protected and advanced therapeutic products
for simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for the
6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
The company’s first two products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG, are topical antimicrobial
products. Currently in routine use, PluroGel™ TAG is showing superior results at the University of Virginia Medical
Center on more than 2,000 patients, both chronic wound and burn. PluroGen’s management team, operational
partners, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen’s
target markets of wound care and burn care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
About Bio Life Tech Conference 2007
Bio Life Tech 2007 is the venture capital showcase for promising young companies. It serve as a gathering place
for entrepreneurs and those organizations funding and servicing them in order to enable them to grow and
succeed. Bio Life Tech is as a part of Early Stage East, founded in 1998 as a non-profit organization, and grown
from a single-day venture capital fair to a year-round series of programs & events. Events showcase
entrepreneurs from up and down the East Coast in order for them to effectively obtain venture capital and
successfully start break-away businesses.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.